From COVID to Flu: mRNA Technology Scores Its Biggest Win Yet
What Happened
The U.S. FDA has approved mFlusiva (mRNA-1010) from Moderna, making it the first mRNA-based influenza vaccine approved in the United States. The vaccine is approved for adults aged 50 and above and uses the same mRNA technology that powered many COVID-19 vaccines.
Key Takeaways
This isn't just a new flu shot. Many scientists see it as the beginning of a new era in vaccine development because mRNA vaccines can be updated much faster than traditional flu vaccines. While conventional flu shots can take up to six months to produce, mRNA-based vaccines may be adapted in a matter of weeks, helping health authorities respond more quickly to evolving flu strains.